National Oncology Institute — Clinical Trial Site

10 Registered trials

1 Currently recruiting

Organisation

National Oncology Institute

Location

Bratislava, Slovakia

Identifier

ORG-100045900

Address

Klenova 1, 833 10, Slovakia

Departments

Clinic of Oncology-Hematology
Department of Clinical Oncology E
Dpt. of Clinical Oncology
Klinika klinickej onkológie Slovenskej zdravotníckej univerzity a Národného onkologického ústavu
klinika onkohematologie
N/A
Oddelenie klinickej onkologie E
Oddelenie klinickej onkológie G
Onco-hematology II
Onkologicka klinika LFUK a NOLI

Clinical trials at this site (10)

Search interface

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01
A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou… Ended

2025-522598-12-00 Untreated Metastatic Pancreatic Ductal Adenocarcinoma 10 2025-12-17
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Follicular Lymphoma 5 2024-05-23
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended

2023-504195-14-00 PD-L1-negative metastatic triple-negative breast cancer 5 2022-08-31
A Phase 1/2a study of PF-07220060 in Participants with Advanced Solid Tumors Ended

2024-512120-11-00 Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast 7 2022-08-31
The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec… Ended

2024-512038-13-00 Metastatic or unresectable locally advanced BRAF V600E/ 5 2021-09-16
Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Newly-diagnosed high-intermediate and high-risk diffuse 5 2021-04-23
A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended

2023-509405-77-00 Colorectal cancer (BRAF V600E-mutant mCRC) 5 2021-02-16
Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended

2023-509471-17-00 Metastatic or unresectable locally advanced BRAF V600E/ 4 2023-05-24
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma Ended

2023-505672-30-00 Unresectable or Metastatic Melanoma 4 2023-02-10